Weekly News Roundup: Abbott Laboratories (NYSE:ABT)

Here’s this week’s run-down of Abbott Laboratories (NYSE:ABT) news briefings. Abbott Laboratories (NYSE:ABT) shares ended the week at 47.92 (as of 1/21/2011). Weekly News Roundup: Abbott Laboratories (NYSE:ABT) Tuesday 18 January Abbott Laboratories (NYSE:ABT) has announced Ozespa will be withdrawn from marketing consideration. This Ozespa medicine, which was under review by the company's Committee for Medicinal Products for Human Use (CHMP), was intended to be used as a solution for chronic plaque psoriasis in adults who were not responding to other systemic therapies like ciclosporin, methotrexate and PUVA. Abbott Laboratories (NYSE:ABT) said in a statement that its decision to withdraw Ozespa was based on the views of the rapporteurs on their 80 days assessment reports. Wednesday 19 January Abbott Laboratories (NYSE:ABT) has announced it will settle its dispute with Depomed Inc. Depomed Inc said in a statement on Tuesday that this drug candidate for shingles-related pain had been launched by the company and subsequently licensed to a subsidiary of Abbott Laboratories (NYSE:ABT) in North Chicago. They are waiting for approval from the U.S. Food and Drug Administration which could come before January 30. Abbott Laboratories (NYSE:ABT) spokeswoman Adela Infante said that “Abbott has complied and will continue to comply with the terms of our agreement with Depomed.” We will continue checking the Abbott Laboratories stock price for changes over the next few weeks.
Negocioenlinea
tdp2664
E money daily